Tuesday

Plenary session features phase III data with implications for standards of care

Monday’s Plenary Session featured five randomized phase III trials spanning breast, liver, brain and prostate cancer, with implications for standards of care.

Keynote I Ezekiel Emanuel, MD, PhD, architects the blueprint for healthcare reform

Keynote speaker Ezekiel Emanuel, MD, PhD, outlined five goals and an eight-point plan for reforming the U.S. healthcare system and radiation oncology’s role.

ASTRO President Vapiwala urges members to move from data to dialogue

In her Presidential Address, ASTRO President Neha Vapiwala, MD, FASTRO, urged the field to move from data to dialogue in communicating radiotherapy’s value.

Fractionated SRS improves local control for larger resected brain metastases: Results of Alliance A071801

Alliance A071801 found fractionated SRS boosted surgical-bed control over single-fraction SRS for resected brain metastases, with an unexpected survival signal.

SRS versus hippocampal-avoidant WBRT for SCLC brain metastases: Results from NRG-CC009

NRG-CC009 addresses a long-standing evidence gap in brain metastasis management for patients with small cell lung cancer, directly comparing stereotactic radiosurgery with hippocampal avoidance WBRT.

Proton therapy does not improve survival over photon therapy in advanced HCC: Initial results of NRG-GI003

Initial results from the phase III NRG-GI003 trial show proton therapy did not improve survival over photon radiotherapy in advanced hepatocellular carcinoma.

Are all grade 1 meningioma equal?

An integrated biomarker study suggests Rb1-S780 phosphorylation may identify aggressive grade 1 meningiomas that could benefit from adjuvant radiation therapy.

Beyond prediction: Linking CT imaging phenotypes to metastatic risk and tumor biology

A multicenter deep radiomics study links CT imaging phenotypes to distant metastasis risk and tumor biology across 3,421 patients with head and neck cancer.